Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: A hospital-based study

International Journal of Rheumatic Diseases

Volumn 15, Issue 3, 2012, Pages 297-305

  Yu, Shan Fu ^a   Chou, Ching Lan ^a   Lai, Han Ming ^a   Chen, Ying Chou ^a   Chiu, Chun Kai ^a   Kuo, Ming Chun ^a   Su, Yu Jih ^a   Chen, Chung Jen ^a   Cheng, Tien Tsai ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Adherence; Compliance; Osteoporosis; Persistence; Taiwan

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; SALCATONIN;

AGED; ARTICLE; DRUG EFFICACY; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN; TREATMENT DURATION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY CONSERVATION AGENTS; DRUG PRESCRIPTIONS; FEMALE; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TAIWAN; TIME FACTORS;

EID: 84862801668     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2012.01719.x     Document Type: Article

References (44)

1. Cooper C, Melton LJ III (1992) Epidemiology of osteoporosis. Trends Endocrinol Metab 3, 224-9.
2. Yang NP, Deng CY, Chou YJ, et al. (2006) Estimated prevalence of osteoporosis from a Nationwide Health Insurance database in Taiwan. Health Policy 75, 329-37.
3. Chie WC, Yang RS, Liu JP, Tsai KS (2004) High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database. Osteoporos Int 15, 998-1002.
4. Liou MJ, Tsai JS, Lin JD (2002) Hip fractures: an increasing geriatric problem in Taiwan. Age Ageing 31, 483-5.
5. Huang KY, Chang JK, Ling SY, Endo N, Takahashi HE (2000) Epidemiology of cervical and trochanteric fractures of the proximal femur in 1996 in Kaohsiung City, Taiwan. J Bone Miner Metab 18, 89-95.
6. Cummings SR, Black DM, Rubin SM (1989) Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149, 2445-8.
7. Eiskjaer S, Ostgard SE, Jakobsen BW, Jensen J, Lucht U (1992) Years of potential life lost after hip fracture among postmenopausal women. Acta Orthop Scand 63, 293-6.
8. Shao CJ, Hsieh YH, Tsai CH, Lai KA (2009) A nationwide seven-year trend of hip fractures in the elderly population of Taiwan. Bone 44, 125-9.
9. Boonen S, Kay R, Cooper C, et al. (2009) Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. Int J Clin Pract 63, 1792-804.
10. Andrade SE, Walker AM, Gottlieb LK, et al. (1995) Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 332, 1125-31.
11. Billups SJ, Malone DC, Carter BL (2000) The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy 20, 941-9.
12. McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288, 2868-79.
13. Eastell R, Garnero P, Vrijens B, et al. (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72, 408.
14. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14, 965-8.
15. Sebaldt R, Shane L, Pham B, et al. (2004) Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. J Bone Miner Res 19, S445.
16. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15, 1003-8.
17. Elders PJM, Leusink GL, Graafmans WC, et al. (2005) NHG-Standaard osteoporose. Huisarts Wet 48, 559-70.
18. Laan RF (2007) Osteoporosis. Neth J Med 65, 47-8.
19. Dawson-Hughes B, Lindsay R, Khosla S, et al. (2008) Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington, DC.
20. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44, 1496-503.
21. Kanis J, Burlet N, Cooper C, et al. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19, 399-428.
22. Castel H, Bonneh DY, Sherf M, Liel Y (2001) Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int 12, 559-64.
23. Solomon DH, Brookart A, Gandhi TK, et al. (2004) Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med 117, 919-24.
24. Cramer JA, Roy A, Burrell A, et al. (2008) Medication compliance and persistence: terminology and definitions. Value Health 11, 44-7.
25. Solomon DH, Avorn J, Katz JN, et al. (2005) Compliance with osteoporosis medications. Arch Intern Med 165, 2414-9.
26. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38, 922-8.
27. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17, 1645-52.
28. Cotte FE, Mercier F, De Pouvourville G (2008) Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 30, 2410-22.
29. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 22, 1537-46.
30. Landfeldt E, Ström O, Robbins S, Borgström F (2011) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23, 433-43.
31. Sheffer A, Taggart V (1993) The National Asthma Education Program: expert panel report guidelines for the diagnosis and management of asthma. Med Care 31, MS20-8.
32. Micieli G, Cavallini A, Quaglini S (2002) Guideline compliance improves stroke outcome: a preliminary study in 4 districts in the Italian region of Lombardia. Stroke 33, 1341-7.
33. Swedberg K, Ekman I (2005) Integrating heart failure guidelines into clinical practice. Eur Heart J 7(Suppl. J), J21-5.
34. Atreja A, Bellam N, Levy S (2005) Strategies to enhance patient adherence: making it simple. MedGenMed 7, 4.
35. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24, 37-55.
36. Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11, 533-6.
37. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353, 487-97.
38. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82, 1493-501.
39. Lin TC, Yang CY, Yang YH, Lin SJ (2011) Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther 90, 109-16.
40. Black DM, Cummings SR, Karpf DB, et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348, 1535-41.
41. Ettinger B, Black DM, Mitlak BH, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637-45.
42. Grady D, Herrington D, Bittner V, et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288, 49-57.
43. Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17, 922-8.
44. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28, 236-42.